1. Skipper HE, Schabel FM, Trader MW, Laster WR (1969) Response to therapy of spontaneous, first passage, and long passage lines of acute leukemia. Cancer Chemother Rep 53: 345–366
2. Urbanitz D, Büchner Th, Pielken H, van de Loo J (1983) Immunotherapy in the treatment of acute myelogeneous leukemia (AML): rationale, results and future prospects. Klin Wochenschr 62: 954
3. Bekesi JG, Holland JF (1979) Impact of specific immunotherapy in acute myelocytic leukemia. In: Neth R, Gallo RC, Hofschneider HP, Mannweiler K (eds) Modern trends in human leukemia, vol 3. Springer, Berlin Heidelberg New York, pp 79–87
4. Bennett JM, Catovsky D, Daniel MTh, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of acute leukemias. Br J Haematol 33: 451–456
5. Büchner Th, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD et al. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin On-col 3: 1583–1589